Deep knowledge on
small-molecule drugs and
the 100,000 global patents
covering them

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

How are People Using DrugPatentWatch?

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: VYVANSE

« Back to Dashboard
Vyvanse is a drug marketed by Shire Development and is included in one NDA. It is available from three suppliers. There are eighteen patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and forty-one patent family members in twenty-five countries.

The generic ingredient in VYVANSE is lisdexamfetamine dimesylate. There is one drug master file entry for this compound. Three suppliers are listed for this compound. There are five tentative approvals for this compound. Additional details are available on the lisdexamfetamine dimesylate profile page.

Summary for Tradename: VYVANSE

Patents:18
Applicants:1
NDAs:1
Suppliers / Packagers: see list18
2013 Sales:$1,743,115,000

Pharmacology for Tradename: VYVANSE

Clinical Trials for: VYVANSE

Effect of Vyvanse on Driving in Young Adults With ADHD
Status: Completed Condition: Attention Deficit/Hyperactivity Disorder(ADHD)

Effect of Vyvanse on Sleep in Children Aged 6-12 Years With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Completed Condition: Attention Deficit Hyperactivity Disorder; Sleep

A Drug Interaction Study of SPD503 and Vyvanse Administered Alone and In Combination in Normal Healthy Volunteers
Status: Completed Condition: Healthy

Vyvanse and Glucose Intolerance in Children With Attention Deficit Hyperactivity Disorder (ADHD) and Obesity
Status: Terminated Condition: Attention Deficit Hyperactivity Disorder; Glucose Intolerance; Obesity

Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC
Status: Completed Condition: Healthy Volunteers

Magnetic Resonance Imaging Study of Lisdexamfetamine for Bipolar Depression
Status: Terminated Condition: Bipolar Depression

Cardiovascular Study of Lisdexamfetamine in Healthy and Hypertensive Attention Deficit Hyperactivity Disorder Adults
Status: Completed Condition: Attention Deficit Hyperactivity Disorder (ADHD)

Shire SCT: Lisdexamfetamine Treatment for ADHD and SCT
Status: Recruiting Condition: Attention Deficit Disorder; Attention Deficit Hyperactivity Disorder

The Effects of Vyvanse(TM) on Brain Hemodynamics and Reading
Status: Completed Condition: Attention Deficit/Hyperactivity Disorder

Pilot Study of Lisdexamfetamine for Treatment of Cocaine Dependence
Status: Completed Condition: Cocaine Dependence

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Shire Development
VYVANSE
lisdexamfetamine dimesylate
CAPSULE;ORAL021977-005Dec 10, 2007RXNo7,678,771<disabled>Y <disabled>
Shire Development
VYVANSE
lisdexamfetamine dimesylate
CAPSULE;ORAL021977-006Dec 10, 2007RXNo7,659,254<disabled> <disabled>
Shire Development
VYVANSE
lisdexamfetamine dimesylate
CAPSULE;ORAL021977-001Feb 23, 2007RXNo7,659,254<disabled> <disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: VYVANSE

Drugname Dosage Strength RLD Submissiondate
lisdexamfetamine dimesylateCapsules20 mg, 30 mg, 40 mg, 50 mg, 60 mg and 70 mgVyvanse2/23/2011

International Patent Family for Tradename: VYVANSE

Country Document Number Publication Date
Singapore147485Nov 28, 2008
World Intellectual Property Organization (WIPO)0234237May 02, 2002
Australia2004277400Apr 14, 2005
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2016 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc